259 related articles for article (PubMed ID: 29170891)
1. AMPK and cardiac remodelling.
Feng Y; Zhang Y; Xiao H
Sci China Life Sci; 2018 Jan; 61(1):14-23. PubMed ID: 29170891
[TBL] [Abstract][Full Text] [Related]
2. AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation.
Daskalopoulos EP; Dufeys C; Bertrand L; Beauloye C; Horman S
J Mol Cell Cardiol; 2016 Feb; 91():188-200. PubMed ID: 26772531
[TBL] [Abstract][Full Text] [Related]
3. Aldolase promotes the development of cardiac hypertrophy by targeting AMPK signaling.
Li Y; Zhang D; Kong L; Shi H; Tian X; Gao L; Liu Y; Wu L; Du B; Huang Z; Liang C; Wang Z; Yao R; Zhang Y
Exp Cell Res; 2018 Sep; 370(1):78-86. PubMed ID: 29902536
[TBL] [Abstract][Full Text] [Related]
4. Exacerbated cardiac fibrosis induced by β-adrenergic activation in old mice due to decreased AMPK activity.
Wang J; Song Y; Li H; Shen Q; Shen J; An X; Wu J; Zhang J; Wu Y; Xiao H; Zhang Y
Clin Exp Pharmacol Physiol; 2016 Nov; 43(11):1029-1037. PubMed ID: 27389807
[TBL] [Abstract][Full Text] [Related]
5. AMP-activated protein kinase in the control of cardiac metabolism and remodeling.
Horman S; Beauloye C; Vanoverschelde JL; Bertrand L
Curr Heart Fail Rep; 2012 Sep; 9(3):164-73. PubMed ID: 22767403
[TBL] [Abstract][Full Text] [Related]
6. AMPK in Cardiovascular Diseases.
Daskalopoulos EP; Dufeys C; Beauloye C; Bertrand L; Horman S
Exp Suppl; 2016; 107():179-201. PubMed ID: 27812981
[TBL] [Abstract][Full Text] [Related]
7. Berberine treatment prevents cardiac dysfunction and remodeling through activation of 5'-adenosine monophosphate-activated protein kinase in type 2 diabetic rats and in palmitate-induced hypertrophic H9c2 cells.
Chang W; Zhang M; Meng Z; Yu Y; Yao F; Hatch GM; Chen L
Eur J Pharmacol; 2015 Dec; 769():55-63. PubMed ID: 26522928
[TBL] [Abstract][Full Text] [Related]
8. Failure to sense energy depletion may be a novel therapeutic target in chronic kidney disease.
Kikuchi H; Sasaki E; Nomura N; Mori T; Minamishima YA; Yoshizaki Y; Takahashi N; Furusho T; Arai Y; Mandai S; Yamashita T; Ando F; Maejima Y; Isobe K; Okado T; Rai T; Uchida S; Sohara E
Kidney Int; 2019 Jan; 95(1):123-137. PubMed ID: 30455054
[TBL] [Abstract][Full Text] [Related]
9. AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism.
Sung MM; Zordoky BN; Bujak AL; Lally JS; Fung D; Young ME; Horman S; Miller EJ; Light PE; Kemp BE; Steinberg GR; Dyck JR
Cardiovasc Res; 2015 Jul; 107(2):235-45. PubMed ID: 26023060
[TBL] [Abstract][Full Text] [Related]
10. Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy?
Li T; Jiang S; Yang Z; Ma Z; Yi W; Wang D; Yang Y
Cell Mol Life Sci; 2017 Apr; 74(8):1413-1429. PubMed ID: 27815596
[TBL] [Abstract][Full Text] [Related]
11. Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis: a potential strategy to prevent the development of cardiac hypertrophy.
Chan AY; Dyck JR
Can J Physiol Pharmacol; 2005 Jan; 83(1):24-8. PubMed ID: 15759047
[TBL] [Abstract][Full Text] [Related]
12. Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response.
Shimano M; Ouchi N; Shibata R; Ohashi K; Pimentel DR; Murohara T; Walsh K
J Mol Cell Cardiol; 2010 Aug; 49(2):210-20. PubMed ID: 20206634
[TBL] [Abstract][Full Text] [Related]
13. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure.
Beauloye C; Bertrand L; Horman S; Hue L
Cardiovasc Res; 2011 May; 90(2):224-33. PubMed ID: 21285292
[TBL] [Abstract][Full Text] [Related]
14. CHIP protects against cardiac pressure overload through regulation of AMPK.
Schisler JC; Rubel CE; Zhang C; Lockyer P; Cyr DM; Patterson C
J Clin Invest; 2013 Aug; 123(8):3588-99. PubMed ID: 23863712
[TBL] [Abstract][Full Text] [Related]
15. Myostatin regulates energy homeostasis in the heart and prevents heart failure.
Biesemann N; Mendler L; Wietelmann A; Hermann S; Schäfers M; Krüger M; Boettger T; Borchardt T; Braun T
Circ Res; 2014 Jul; 115(2):296-310. PubMed ID: 24807786
[TBL] [Abstract][Full Text] [Related]
16. Cardiac-specific overexpression of farnesyl pyrophosphate synthase induces cardiac hypertrophy and dysfunction in mice.
Yang J; Mou Y; Wu T; Ye Y; Jiang JC; Zhao CZ; Zhu HH; Du CQ; Zhou L; Hu SJ
Cardiovasc Res; 2013 Mar; 97(3):490-9. PubMed ID: 23180723
[TBL] [Abstract][Full Text] [Related]
17. Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone+salt-induced cardiac fibrosis in vivo.
Mummidi S; Das NA; Carpenter AJ; Kandikattu H; Krenz M; Siebenlist U; Valente AJ; Chandrasekar B
J Mol Cell Cardiol; 2016 Sep; 98():95-102. PubMed ID: 27423273
[TBL] [Abstract][Full Text] [Related]
18. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy.
Li HL; Yin R; Chen D; Liu D; Wang D; Yang Q; Dong YG
J Cell Biochem; 2007 Apr; 100(5):1086-99. PubMed ID: 17266062
[TBL] [Abstract][Full Text] [Related]
19. AMPK signalling and the control of substrate use in the heart.
Nagendran J; Waller TJ; Dyck JR
Mol Cell Endocrinol; 2013 Feb; 366(2):180-93. PubMed ID: 22750050
[TBL] [Abstract][Full Text] [Related]
20. Subcellular remodelling may induce cardiac dysfunction in congestive heart failure.
Dhalla NS; Saini-Chohan HK; Rodriguez-Leyva D; Elimban V; Dent MR; Tappia PS
Cardiovasc Res; 2009 Feb; 81(3):429-38. PubMed ID: 18852252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
